Danaher and Fudan University’s Huashan Hospital Partner to Develop Alzheimer’s Diagnosis Technology

 

 

On January 20, Danaher, a global leader in science and technology innovation, announced that its operating company, Beckman Coulter Diagnostics (Suzhou) Co., Ltd., has partnered with Fudan University’s Huashan Hospital to jointly develop innovative solutions for the early and differential diagnosis of Alzheimer’s disease (AD). This collaboration marks Danaher’s first Danaher Beacon research project in China.

 

Under the leadership of Professor Yu Jintai from Huashan Hospital's Neurology Department, the project will leverage high-sensitivity diagnostic technology platforms to explore the relationship between novel blood biomarkers and clinical outcomes in Alzheimer’s disease. The collaboration aims to accelerate the clinical application of blood biomarkers, improve the accuracy of early and differential diagnoses, optimize treatment plans, delay disease progression, and enhance patient quality of life. Furthermore, this diagnostic technology holds the potential for application in diagnosing other types of neurodegenerative and neuroimmune diseases.

 

 

Over 1 Billion CNY Investment! Siemens Lays Foundation for New R&D and Manufacturing Base

 

 

On January 18, the groundbreaking ceremony for Siemens Maidite (shenzhen) Magnetic Resonance Co., Ltd.'s new high-end medical equipment R&D and manufacturing base was held in Shenzhen. The ceremony was attended by Siemens Healthineers board member Elisabeth Staudinger, Wang Hao, President of Siemens Healthineers Greater China and member of the Global Leadership Team, Carsten Bertram, President of Siemens Healthineers Clinical Therapy Systems, Andreas Schneck, Global Vice President of the Magnetic Resonance Division, and Ma Tianshi, General Manager of Siemens Shenzhen Magnetic Resonance Ltd.

 

The project represents a total investment exceeding 1 billion CNY, covering an area of 63,000 square meters with a planned construction area of 98,000 square meters. The facility is expected to be operational by the end of 2027 at the latest. The new base will focus on R&D and production of vascular imaging equipment and core magnetic resonance components, including Siemens Healthineers’ latest DryCool superconducting magnets.

 

 

Upon completion, the new facility will operate in conjunction with the current base under a “dual-site” model, forming the Siemens Healthineers Shenzhen Innovation Industrial Park. This expansion will triple the scale of Siemens’ Shenzhen operations and enhance production capacity. The new base is designed to integrate R&D, production, talent cultivation, and open innovation, creating a multifunctional hub for medical equipment that will inject fresh momentum into global healthcare development.

 

 

YHLO and The Chinese University of Hong Kong (Shenzhen) Sign Industry-Academia-Research Cooperation Agreement

 

 

On January 13, the finals and award ceremony of the 2nd The CUHK-Shenzhen Fairy Lake International Innovation and Entrepreneurship Competition, hosted by The Chinese University of Hong Kong (Shenzhen), were held successfully. Hu Deming, Founder of YHLO, Hu Kunhui, Chairman and CEO, and Cheng Bangning, Chief Clinical Expert and Director of the Industry-Academia-Research Development Department, attended the event. Representing the company, they signed a strategic industry-academia-research collaboration agreement with The Chinese University of Hong Kong (Shenzhen). Both parties aim to pursue deeper collaborations in the biomedical industry.

 

 

Under the agreement, YHLO will collaborate with Professor Du Yang and Professor Du Juan’s teams from the university to focus on rapid early diagnostic technologies and the development of novel biomarker standards for major diseases. The partnership will target cardiovascular and metabolic diseases, fostering industry-academia-research collaboration and innovation in scientific research and clinical diagnostic product transformation. Building on the university's achievements in neuropsychiatric diagnostic technologies and drug discovery, the partnership will also explore advanced diagnostic technologies for neuropsychiatric diseases and promote the clinical application of basic scientific results through medical-engineering integration.

 

 

Autobio Diagnostics and Boditech Med Establish Strategic Partnership

 

 

On January 13, Autobio Diagnostics and Boditech Med held a grand signing ceremony for their strategic partnership at Boditech's campus in Chuncheon, South Korea. Attendees included Fu Guangyu, Executive Vice President of Autobio Diagnostics, and Eui Yul Choi, CEO of Boditech Med. Both parties will leverage their respective strengths in the in vitro diagnostics (IVD) field to engage in in-depth cooperation in the area of immunodiagnostics.

 

During the event, both parties engaged in thorough discussions regarding their strategic collaboration. Fu Guangyu highlighted Autobio's achievements in innovation and development, and also stating, “This strategic partnership represents complementary strengths and collaborative innovation between Autobio and Boditech Med. We believe this collaboration will bring new opportunities and broader growth prospects for both parties. We look forward to working hand in hand with Boditech Med to achieve mutual growth and shared success.”

 

 

This signing ceremony marks a new chapter in the collaboration between Autobio Diagnostics and Boditech Med in the IVD field. Meanwhile, they aim to explore the Korean market, promote innovation in immunodiagnostic technologies, and deliver more precise and efficient products and services to patients worldwide.